These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15555873)

  • 1. Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa.
    Zhanel GG; Hoban DJ; Schurek K; Karlowsky JA
    Int J Antimicrob Agents; 2004 Dec; 24(6):529-35. PubMed ID: 15555873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of cell wall organization and active efflux pump systems in multidrug resistance of bacteria].
    Hasdemir U
    Mikrobiyol Bul; 2007 Apr; 41(2):309-27. PubMed ID: 17682720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
    Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections.
    Burgess DS
    Clin Infect Dis; 2005 Feb; 40 Suppl 2():S99-104. PubMed ID: 15712103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new member of the tripartite multidrug efflux pumps, MexVW-OprM, in Pseudomonas aeruginosa.
    Li Y; Mima T; Komori Y; Morita Y; Kuroda T; Mizushima T; Tsuchiya T
    J Antimicrob Chemother; 2003 Oct; 52(4):572-5. PubMed ID: 12951344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa.
    Dupont P; Hocquet D; Jeannot K; Chavanet P; Plésiat P
    J Antimicrob Chemother; 2005 Apr; 55(4):518-22. PubMed ID: 15722391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of Pseudomonas aeruginosa.
    Wong-Beringer A; Wiener-Kronish J; Lynch S; Flanagan J
    Clin Microbiol Infect; 2008 Apr; 14(4):330-6. PubMed ID: 18190571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of Pseudomonas aeruginosa isolated from clinical and environmental samples in Minia, Egypt: prevalence, antibiogram and resistance mechanisms.
    Gad GF; El-Domany RA; Zaki S; Ashour HM
    J Antimicrob Chemother; 2007 Nov; 60(5):1010-7. PubMed ID: 17906321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions.
    Schweizer HP
    Genet Mol Res; 2003 Mar; 2(1):48-62. PubMed ID: 12917802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
    Pasquali F; Manfreda G
    Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of transcriptional activators RamA and SoxS on expression of multidrug efflux pumps AcrAB and AcrEF in fluoroquinolone-resistant Salmonella Typhimurium.
    Zheng J; Cui S; Meng J
    J Antimicrob Chemother; 2009 Jan; 63(1):95-102. PubMed ID: 18984645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efflux-mediated antimicrobial resistance.
    Poole K
    J Antimicrob Chemother; 2005 Jul; 56(1):20-51. PubMed ID: 15914491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of multiple drug resistance efflux pumps of pathogenic bacteria.
    Rouveix B
    J Antimicrob Chemother; 2007 Jun; 59(6):1208-9. PubMed ID: 17507420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
    Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical consequences of antimicrobial resistance.
    Rice LB
    Curr Opin Microbiol; 2009 Oct; 12(5):476-81. PubMed ID: 19716760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of fluoroquinolone resistance in Streptococcus pneumoniae clinical isolates and laboratory-derived mutants.
    Smith-Adam HJ; Nichol KA; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2005 Feb; 49(2):846-8. PubMed ID: 15673786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates.
    Coban AY; Ekinci B; Durupinar B
    Chemotherapy; 2004 Apr; 50(1):22-6. PubMed ID: 15084801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Selected mechanisms of resistance to antimicrobial drugs in Pseudomonas aeruginosa and their detection].
    Liptáková A; Siegfried L; Jarcuska P; Schrér I
    Klin Mikrobiol Infekc Lek; 2005 Jun; 11(3):109-11. PubMed ID: 16025430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
    Sierra JM; Cabeza JG; Ruiz Chaler M; Montero T; Hernandez J; Mensa J; Llagostera M; Vila J
    Clin Microbiol Infect; 2005 Sep; 11(9):750-8. PubMed ID: 16104991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro effectiveness of the antibiotic lock technique (ALT) for the treatment of catheter-related infections by Pseudomonas aeruginosa and Klebsiella pneumoniae.
    Lee MY; Ko KS; Song JH; Peck KR
    J Antimicrob Chemother; 2007 Oct; 60(4):782-7. PubMed ID: 17681978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.